The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

Novo Nordisk's recent decline suggests it may be a Buy again, with strong growth prospects in diabetes and obesity treatments ...

On the charts, today's pop has NVO on track to snap a three-day losing streak. The stock still hasn't recovered from its mid-December bear gap, after which it hit a Jan. 17, 52-week low of $78.17 amid ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

Christina Aguilera has lost her famous curves – and weight loss drug Ozempic is to blame, with the pop superstar now barely ...

Pharma giant Novo Nordisk, the company behind Wegovy and Ozempic, expects to launch six products in the next five years. Leading the pack of new drugs will be CagriSema.

Dr. Scott Loessin, a distinguished board-certified plastic surgeon, is redefining body contouring for individuals who have achieved significant weight loss through medications like Ozempic or other ...

For those not following along, here's a comprehensive breakdown of everything that's been said in the studio, on stage (and ...

Novo Nordisk NVO is scheduled to report fourth-quarter 2024 results on Feb. 5, 2025, before the opening bell. The Zacks ...

Jim Cramer, the host of Mad Money, discussed the upcoming market and corporate activity to look forward to this week, which ...

Atlanta’s chapter of the Party for Socialism and Liberation, or PSL, held an organizing meeting at the Little Five Points ...